奋力谱写世界一流企业建设新篇章 扬子江药业召开2025年年终工作会议

Core Viewpoint - Yangtze River Pharmaceutical Group is making significant strides in innovation, internationalization, and sustainable development, aiming to become a world-class pharmaceutical and health industry group by leveraging its strengths in research and development, smart manufacturing, and quality control [1][3][5][6] Group 1: Achievements and Innovations - The company has launched several innovative products, including the traditional Chinese medicine Yiqi Tongqiao Wan and the chemical drug Tadalafil, with over 140 major research projects undertaken [3] - International revenue has increased by 425% year-on-year, with a 239% increase in the health sector's income, and the number of overseas collaborations has expanded by 238% [3] - The company has received numerous national honors, including being the first non-listed pharmaceutical company to achieve "EFQM Global Award" RbE seven-star certification and ranking first in ESG ratings among non-listed pharmaceutical firms [3][5] Group 2: Future Plans and Strategic Goals - The company aims to focus on digital transformation, green development, and high-end upgrades during the "14th Five-Year Plan" period, with 2026 designated as the "Year of Internationalization" [6] - Plans include enhancing innovation capabilities, optimizing industry structure, and expanding overseas market presence to improve global resource allocation [6] - The company is committed to maintaining high-quality standards and actively participating in standard-setting to enhance the reputation of "Yangtze River Quality" in international markets [5][6]